News | April 02, 2008

RIA Chooses AMICAS to Streamline Imaging Management

April 3, 2008 - AMICAS Inc. is partnering with one of the nation’s largest radiology practices, Radiology Imaging Associates (RIA) of Denver, CO, a partnership designed to allow AMICAS to apply its medical image and information management tools as part of RIA’s customer service and outpatient growth initiatives.

Under the terms of the agreement, RIA will utilize new modular, Web-based technology to customize an integrated scheduling, billing, marketing and tracking system. Included in the partnership deal are AMICAS Vision Series RIS, Vision Reach, Insight Dashboards and Vision Series Document Management solutions.

Vision Series RIS, which is completely Web-based, provides charge capture, patient flow monitoring, mammography tracking, as well as the ability to fax and e-mail results to referring physicians. Vision Reach is reportedly an innovative zero client results distribution tool and portal designed specifically for referring physicians.

Insight Dashboards, a Web-based business intelligence platform, provides access to customized, near real time data for key performance metrics and indicators, including both clinical and operational factors. An enterprise solution, Vision Series Document Management provides electronic capture, storage and management of every document in an independent radiology business.

For more information: www.amicas.com

Related Content

ISMRM Issues Guidelines for MRI Gadolinium Contrast Agents
News | Contrast Media | August 15, 2017
The International Society for Magnetic Resonance in Medicine (ISMRM) has provided new guidance in the use of contrast...
Contrast Media from Bayer, trends in contrast media and developments in contrast media
Feature | Contrast Media | July 28, 2017 | By Dave Fornell
Here are several updates in medical imaging ...
Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media | July 18, 2017
July 18, 2017 — Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabri
ACR Offers Revised Contrast Media in Imaging Manual
News | Contrast Media | July 17, 2017
The American College of Radiology (ACR) recently revised its authoritative guide for the safe and effective use of...
FDA says gadolinium retention in the brain is not a safety issue
Feature | Magnetic Resonance Imaging (MRI) | May 25, 2017
A U.S. Food and Drug Administration (FDA) review of the safety ramifications of gadolinium-based contrast agents for...
Targeted MRI Could Pinpoint Aggressive Prostate Cancers Before They Spread

The ZD2-Gd probe, represented by the orange ball and green arrow, binds to the EDB-FN in the prostate cancer cells with high metastatic potential. This results in a strong MRI signal (upper right). Prostate cancer cells with low metastatic potential have no EDB-FN and so there is no MRI signal (lower right). Credit: Han, et al., Bioconjug Chem-Apr-2017

News | Prostate Cancer | May 24, 2017
A research team funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) has engineered a...
Scientists Develop Novel Chemical Dye to Improve MRI Liver Cancer Imaging
News | Magnetic Resonance Imaging (MRI) | May 03, 2017
May 3, 2017 — Scientists from the National University of Singapore (NUS) have developed a novel nanodiamond-based ...
Sponsored Content | Case Study | Contrast Media Injectors | April 13, 2017
The volume of computed tomography (CT) imaging exams continues to grow in the United States,[2] adding pressure to...
PRAC, European Medicines Agency, gadolinium-based contrast agents, safety recommendations, brain MRI
News | Contrast Media | March 13, 2017
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recently released new...
Overlay Init